{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:34:15Z","timestamp":1793090055420,"version":"4.5.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00223-020-00691-6","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T08:02:42Z","timestamp":1591344162000},"page":"128-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":153,"title":["Tumor-Induced Osteomalacia"],"prefix":"10.1007","volume":"108","author":[{"given":"Pablo","family":"Florenzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris R.","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Roszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel I.","family":"Gafni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"issue":"5","key":"691_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1172\/JCI108855","volume":"60","author":"MK Drezner","year":"1977","unstructured":"Drezner MK, Feinglos MN (1977) Osteomalacia due to 1alpha, 25-dihydroxycholecalciferol deficiency. Association with a giant cell tumor of bone. J Clin Investig 60(5):1046\u20131053","journal-title":"J Clin Investig"},{"key":"691_CR2","doi-asserted-by":"publisher","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","volume":"3","author":"S Minisola","year":"2017","unstructured":"Minisola S et al (2017) Tumour-induced osteomalacia. Nat Rev Dis Primers 3:17044","journal-title":"Nat Rev Dis Primers"},{"key":"691_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bonr.2017.09.002","volume":"7","author":"P Florenzano","year":"2017","unstructured":"Florenzano P, Gafni RI, Collins MT (2017) Tumor-induced osteomalacia. Bone Rep 7:90\u201397","journal-title":"Bone Rep"},{"key":"691_CR4","first-page":"554","volume":"14","author":"A Prader","year":"1959","unstructured":"Prader A et al (1959) Rickets following bone tumor. Helv Paediatr Acta 14:554\u2013565","journal-title":"Helv Paediatr Acta"},{"issue":"2","key":"691_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1210\/jcem.86.2.7408","volume":"86","author":"KE White","year":"2001","unstructured":"White KE et al (2001) The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86(2):497\u2013500","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"691_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/81664","volume":"26","author":"ADHR Consortium","year":"2000","unstructured":"ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26(3):345\u2013348","journal-title":"Nat Genet"},{"issue":"11","key":"691_CR7","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada T et al (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98(11):6500\u20136505","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"691_CR8","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa020881","volume":"348","author":"KB Jonsson","year":"2003","unstructured":"Jonsson KB et al (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348(17):1656\u20131663","journal-title":"N Engl J Med"},{"issue":"1","key":"691_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","volume":"28","author":"AL Folpe","year":"2004","unstructured":"Folpe AL et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28(1):1\u201330","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"691_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T et al (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19(3):429\u2013435","journal-title":"J Bone Miner Res"},{"issue":"9","key":"691_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo I et al (2015) Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 62(9):811\u2013816","journal-title":"Endocr J"},{"issue":"9","key":"691_CR12","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/jbmr.1642","volume":"27","author":"Y Jiang","year":"2012","unstructured":"Jiang Y et al (2012) Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res 27(9):1967\u20131975","journal-title":"J Bone Miner Res"},{"issue":"1","key":"691_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/BPB.0b013e32832f59cb","volume":"19","author":"GH Jung","year":"2010","unstructured":"Jung GH et al (2010) A 9-month-old phosphaturic mesenchymal tumor mimicking the intractable rickets. J Pediatr Orthop B 19(1):127\u2013132","journal-title":"J Pediatr Orthop B"},{"issue":"1","key":"691_CR14","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1097\/MPH.0000000000000686","volume":"39","author":"SS Crossen","year":"2017","unstructured":"Crossen SS et al (2017) Tumor-induced osteomalacia in a 3-year-old with unresectable central giant cell lesions. J Pediatr Hematol Oncol 39(1):e21\u2013e24","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"691_CR15","doi-asserted-by":"publisher","first-page":"e1518","DOI":"10.1542\/peds.2014-2218","volume":"135","author":"E Fern\u00e1ndez-Cooke","year":"2015","unstructured":"Fern\u00e1ndez-Cooke E et al (2015) Tumor-induced rickets in a child with a central giant cell granuloma: a case report. Pediatrics 135(6):e1518\u2013e1523","journal-title":"Pediatrics"},{"issue":"6","key":"691_CR16","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/jbmr.1881","volume":"28","author":"WH Chong","year":"2013","unstructured":"Chong WH et al (2013) Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res 28(6):1386\u20131398","journal-title":"J Bone Miner Res"},{"issue":"11","key":"691_CR17","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/jbmr.3219","volume":"32","author":"SH Tella","year":"2017","unstructured":"Tella SH et al (2017) Multimodality image-guided cryoablation for inoperable tumor-induced osteomalacia. J Bone Miner Res 32(11):2248\u20132256","journal-title":"J Bone Miner Res"},{"key":"691_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jbmr.3903","volume":"35","author":"X Li","year":"2019","unstructured":"Li X et al (2019) Nonremission and recurrent tumor-induced osteomalacia: a retrospective study. J Bone Miner Res 35:469\u2013477","journal-title":"J Bone Miner Res"},{"issue":"6","key":"691_CR19","first-page":"E11","volume":"89","author":"NR Peterson","year":"2010","unstructured":"Peterson NR, Summerlin DJ, Cordes SR (2010) Multiple phosphaturic mesenchymal tumors associated with oncogenic osteomalacia: case report and review of the literature. Ear Nose Throat J 89(6):E11\u2013E15","journal-title":"Ear Nose Throat J"},{"issue":"1","key":"691_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12891-017-1446-z","volume":"18","author":"R Arai","year":"2017","unstructured":"Arai R et al (2017) A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia. BMC Musculoskelet Disord 18(1):79","journal-title":"BMC Musculoskelet Disord"},{"issue":"5","key":"691_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1172\/JCI18399","volume":"112","author":"M Riminucci","year":"2003","unstructured":"Riminucci M et al (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Investig 112(5):683\u2013692","journal-title":"J Clin Investig"},{"issue":"5","key":"691_CR22","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.kint.2017.11.018","volume":"93","author":"L Toro","year":"2018","unstructured":"Toro L et al (2018) Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury. Kidney Int 93(5):1131\u20131141","journal-title":"Kidney Int"},{"issue":"1","key":"691_CR23","doi-asserted-by":"publisher","first-page":"F132","DOI":"10.1152\/ajprenal.00081.2017","volume":"314","author":"S Rabadi","year":"2018","unstructured":"Rabadi S et al (2018) Acute blood loss stimulates fibroblast growth factor 23 production. Am J Physiol Ren Physiol 314(1):F132\u2013F139","journal-title":"Am J Physiol Ren Physiol"},{"issue":"12","key":"691_CR24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.tem.2012.07.002","volume":"23","author":"N Bhattacharyya","year":"2012","unstructured":"Bhattacharyya N et al (2012) Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab 23(12):610\u2013618","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"691_CR25","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1002\/jps.22614","volume":"100","author":"K Miyamoto","year":"2011","unstructured":"Miyamoto K et al (2011) Sodium-dependent phosphate cotransporters: lessons from gene knockout and mutation studies. J Pharm Sci 100(9):3719\u20133730","journal-title":"J Pharm Sci"},{"key":"691_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-015-9318-z","author":"JE Blau","year":"2015","unstructured":"Blau JE, Collins MT (2015) The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord. https:\/\/doi.org\/10.1007\/s11154-015-9318-z","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"691_CR27","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1359\/jbmr.060507","volume":"21","author":"SM Burnett","year":"2006","unstructured":"Burnett SM et al (2006) Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21(8):1187\u20131196","journal-title":"J Bone Miner Res"},{"issue":"11","key":"691_CR28","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.3324\/haematol.2017.167882","volume":"102","author":"EL Clinkenbeard","year":"2017","unstructured":"Clinkenbeard EL et al (2017) Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica 102(11):e427\u2013e430","journal-title":"Haematologica"},{"issue":"10","key":"691_CR29","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00424-018-2171-7","volume":"470","author":"A Daryadel","year":"2018","unstructured":"Daryadel A et al (2018) Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men. Pflugers Arch 470(10):1569\u20131582","journal-title":"Pflugers Arch"},{"key":"691_CR30","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/ndt\/gfy189","volume":"34","author":"MR Hanudel","year":"2018","unstructured":"Hanudel MR et al (2018) Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol Dial Transplant 34:2057\u20132065","journal-title":"Nephrol Dial Transplant"},{"issue":"4\u20135","key":"691_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3109\/01913129109016242","volume":"15","author":"N Weidner","year":"1991","unstructured":"Weidner N (1991) Review and update: oncogenic osteomalacia-rickets. Ultrastruct Pathol 15(4\u20135):317\u2013333","journal-title":"Ultrastruct Pathol"},{"issue":"2","key":"691_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1023\/A:1010006811394","volume":"2","author":"MK Drezner","year":"2001","unstructured":"Drezner MK (2001) Tumor-induced osteomalacia. Rev Endocr Metab Disord 2(2):175\u2013186","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"691_CR33","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1053\/j.semdp.2019.07.002","volume":"36","author":"AL Folpe","year":"2019","unstructured":"Folpe AL (2019) Phosphaturic mesenchymal tumors: a review and update. Semin Diagn Pathol 36(4):260\u2013268","journal-title":"Semin Diagn Pathol"},{"issue":"8","key":"691_CR34","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/1097-0142(19870415)59:8<1442::AID-CNCR2820590810>3.0.CO;2-Q","volume":"59","author":"N Weidner","year":"1987","unstructured":"Weidner N, Santa Cruz D (1987) Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 59(8):1442\u20131454","journal-title":"Cancer"},{"key":"691_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41379-018-0100-0","volume":"32","author":"H Wu","year":"2018","unstructured":"Wu H et al (2018) Phosphaturic mesenchymal tumor with an admixture of epithelial and mesenchymal elements in the jaws: clinicopathological and immunohistochemical analysis of 22 cases with literature review. Mod Pathol 32:189\u2013204","journal-title":"Mod Pathol"},{"issue":"4","key":"691_CR36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2265.1992.tb02342.x","volume":"37","author":"JN Harvey","year":"1992","unstructured":"Harvey JN, Gray C, Belchetz PE (1992) Oncogenous osteomalacia and malignancy. Clin Endocrinol (Oxf) 37(4):379\u2013382","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"691_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s002560000306","volume":"30","author":"A Ogose","year":"2001","unstructured":"Ogose A et al (2001) Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skelet Radiol 30(2):99\u2013103","journal-title":"Skelet Radiol"},{"issue":"5","key":"691_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/8756-3282(86)90251-6","volume":"7","author":"H Rico","year":"1986","unstructured":"Rico H et al (1986) Oncogenous osteomalacia: a new case secondary to a malignant tumor. Bone 7(5):325\u2013329","journal-title":"Bone"},{"issue":"1","key":"691_CR39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.anl.2008.01.003","volume":"36","author":"N Uramoto","year":"2009","unstructured":"Uramoto N, Furukawa M, Yoshizaki T (2009) Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx 36(1):104\u2013105","journal-title":"Auris Nasus Larynx"},{"issue":"4","key":"691_CR40","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/jcp.30.4.328","volume":"30","author":"AL Wyman","year":"1977","unstructured":"Wyman AL, Paradinas FJ, Daly JR (1977) Hypophosphataemic osteomalacia associated with a malignant tumour of the tibia: report of a case. J Clin Pathol 30(4):328\u2013335","journal-title":"J Clin Pathol"},{"key":"691_CR41","first-page":"18","volume":"2018","author":"MP Yavropoulou","year":"2018","unstructured":"Yavropoulou MP et al (2018) Distant lung metastases caused by a histologically benign phosphaturic mesenchymal tumor. Endocrinol Diabetes Metab Case Rep 2018:18\u20130023","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"9","key":"691_CR42","first-page":"1860","volume":"121","author":"D Sidell","year":"2011","unstructured":"Sidell D et al (2011) Malignant phosphaturic mesenchymal tumor of the larynx. Laryngoscope 121(9):1860\u20131863","journal-title":"Laryngoscope"},{"issue":"17","key":"691_CR43","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMcpc1104567","volume":"365","author":"C Bergwitz","year":"2011","unstructured":"Bergwitz C et al (2011) Case records of the Massachusetts General Hospital. Case 33-2011. A 56-year-old man with hypophosphatemia. N Engl J Med 365(17):1625\u20131635","journal-title":"N Engl J Med"},{"issue":"1","key":"691_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/PAS.0000000000000290","volume":"39","author":"JM Carter","year":"2015","unstructured":"Carter JM et al (2015) A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors. Am J Surg Pathol 39(1):75\u201383","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"691_CR45","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1016\/j.humpath.2013.07.016","volume":"44","author":"M Houang","year":"2013","unstructured":"Houang M et al (2013) Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol 44(12):2711\u20132718","journal-title":"Hum Pathol"},{"issue":"9","key":"691_CR46","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1097\/PAS.0b013e3181aa2311","volume":"33","author":"A Bahrami","year":"2009","unstructured":"Bahrami A et al (2009) RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol 33(9):1348\u20131354","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"691_CR47","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/his.13377","volume":"72","author":"Y Yamada","year":"2018","unstructured":"Yamada Y et al (2018) Histopathological and genetic review of phosphaturic mesenchymal tumours, mixed connective tissue variant. Histopathology 72(3):460\u2013471","journal-title":"Histopathology"},{"issue":"8","key":"691_CR48","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1002\/1097-0142(19850415)55:8<1691::AID-CNCR2820550814>3.0.CO;2-S","volume":"55","author":"N Weidner","year":"1985","unstructured":"Weidner N et al (1985) Neoplastic pathology of oncogenic osteomalacia\/rickets. Cancer 55(8):1691\u20131705","journal-title":"Cancer"},{"issue":"9308","key":"691_CR49","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","volume":"359","author":"SM Jan de Beur","year":"2002","unstructured":"Jan de Beur SM et al (2002) Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359(9308):761\u2013763","journal-title":"Lancet"},{"issue":"4","key":"691_CR50","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/path.4465","volume":"235","author":"JC Lee","year":"2015","unstructured":"Lee JC et al (2015) Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J Pathol 235(4):539\u2013545","journal-title":"J Pathol"},{"issue":"11","key":"691_CR51","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/modpathol.2016.137","volume":"29","author":"JC Lee","year":"2016","unstructured":"Lee JC et al (2016) Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol 29(11):1335\u20131346","journal-title":"Mod Pathol"},{"issue":"10","key":"691_CR52","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1097\/PAS.0000000000000890","volume":"41","author":"A Agaimy","year":"2017","unstructured":"Agaimy A et al (2017) Phosphaturic mesenchymal tumors: clinicopathologic, immunohistochemical and molecular analysis of 22 cases expanding their morphologic and immunophenotypic spectrum. Am J Surg Pathol 41(10):1371\u20131380","journal-title":"Am J Surg Pathol"},{"key":"691_CR53","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.humpath.2018.02.022","volume":"80","author":"KN Sent-Doux","year":"2018","unstructured":"Sent-Doux KN et al (2018) Phosphaturic mesenchymal tumor without osteomalacia: additional confirmation of the \u201cnonphosphaturic\u201d variant, with emphasis on the roles of FGF23 chromogenic in situ hybridization and FN1-FGFR1 fluorescence in situ hybridization. Hum Pathol 80:94\u201398","journal-title":"Hum Pathol"},{"key":"691_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13000-016-0477-3","volume":"11","author":"E Shiba","year":"2016","unstructured":"Shiba E et al (2016) Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant. Diagn Pathol 11:26","journal-title":"Diagn Pathol"},{"issue":"3","key":"691_CR55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s12105-015-0678-1","volume":"10","author":"JK Wasserman","year":"2016","unstructured":"Wasserman JK et al (2016) Phosphaturic mesenchymal tumor involving the head and neck: a report of five cases with FGFR1 fluorescence in situ hybridization analysis. Head Neck Pathol 10(3):279\u2013285","journal-title":"Head Neck Pathol"},{"issue":"2","key":"691_CR56","doi-asserted-by":"publisher","first-page":"275","DOI":"10.7326\/0003-4819-93-2-275","volume":"93","author":"KW Lyles","year":"1980","unstructured":"Lyles KW et al (1980) Hypophosphatemic osteomalacia: association with prostatic carcinoma. Ann Intern Med 93(2):275\u2013278","journal-title":"Ann Intern Med"},{"issue":"9","key":"691_CR57","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00520-012-1474-z","volume":"20","author":"MP Mak","year":"2012","unstructured":"Mak MP et al (2012) Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition. Support Care Cancer 20(9):2195\u20132197","journal-title":"Support Care Cancer"},{"issue":"1","key":"691_CR58","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000282746","volume":"55","author":"H Nakahama","year":"1995","unstructured":"Nakahama H et al (1995) Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Urol Int 55(1):38\u201340","journal-title":"Urol Int"},{"issue":"3 Pt 1","key":"691_CR59","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0022-5347(01)64351-9","volume":"158","author":"DM Reese","year":"1997","unstructured":"Reese DM, Rosen PJ (1997) Oncogenic osteomalacia associated with prostate cancer. J Urol 158(3 Pt 1):887","journal-title":"J Urol"},{"issue":"1","key":"691_CR60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40200-019-00398-y","volume":"18","author":"C Savva","year":"2019","unstructured":"Savva C et al (2019) Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature. J Diabetes Metab Disord 18(1):267\u2013272","journal-title":"J Diabetes Metab Disord"},{"issue":"2","key":"691_CR61","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/1066896915617828","volume":"24","author":"A Sauder","year":"2016","unstructured":"Sauder A et al (2016) FGF23-associated tumor-induced osteomalacia in a patient with small cell carcinoma: a case report and regulatory mechanism study. Int J Surg Pathol 24(2):116\u2013120","journal-title":"Int J Surg Pathol"},{"issue":"12","key":"691_CR62","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1210\/jc.2014-2120","volume":"99","author":"HA Lin","year":"2014","unstructured":"Lin HA et al (2014) Ovarian cancer-related hypophosphatemic osteomalacia\u2014a case report. J Clin Endocrinol Metab 99(12):4403\u20134407","journal-title":"J Clin Endocrinol Metab"},{"key":"691_CR63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bonr.2015.11.004","volume":"5","author":"EG Abate","year":"2016","unstructured":"Abate EG et al (2016) Tumor induced osteomalacia secondary to anaplastic thyroid carcinoma: a case report and review of the literature. Bone Rep 5:81\u201385","journal-title":"Bone Rep"},{"issue":"11","key":"691_CR64","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/RLU.0b013e3182a20ded","volume":"38","author":"X Jin","year":"2013","unstructured":"Jin X et al (2013) Osteomalacia-inducing renal clear cell carcinoma uncovered by 99mTc-hydrazinonicotinyl-Tyr3-octreotide (99mTc-HYNIC-TOC) scintigraphy. Clin Nucl Med 38(11):922\u2013924","journal-title":"Clin Nucl Med"},{"issue":"1","key":"691_CR65","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/jcp.47.1.80","volume":"47","author":"C van Heyningen","year":"1994","unstructured":"van Heyningen C et al (1994) Oncogenic hypophosphataemia and ectopic corticotrophin secretion due to oat cell carcinoma of the trachea. J Clin Pathol 47(1):80\u201382","journal-title":"J Clin Pathol"},{"issue":"6","key":"691_CR66","doi-asserted-by":"publisher","first-page":"786","DOI":"10.7326\/0003-4819-101-6-786","volume":"101","author":"HC Taylor","year":"1984","unstructured":"Taylor HC, Fallon MD, Velasco ME (1984) Oncogenic osteomalacia and inappropriate antidiuretic hormone secretion due to oat-cell carcinoma. Ann Intern Med 101(6):786\u2013788","journal-title":"Ann Intern Med"},{"issue":"5","key":"691_CR67","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1210\/js.2018-00010","volume":"2","author":"RB Reinert","year":"2018","unstructured":"Reinert RB, Bixby D, Koenig RJ (2018) Fibroblast growth factor 23-induced hypophosphatemia in acute leukemia. J Endocr Soc 2(5):437\u2013443","journal-title":"J Endocr Soc"},{"key":"691_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-213954","author":"JH Elderman","year":"2016","unstructured":"Elderman JH, Wabbijn M, de Jongh F (2016) Hypophosphataemia due to FGF-23 producing B cell non-Hodgkin\u2019s lymphoma. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2015-213954","journal-title":"BMJ Case Rep"},{"key":"691_CR69","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-4453","author":"H Wasserman","year":"2016","unstructured":"Wasserman H et al (2016) Two case reports of FGF23-induced hypophosphatemia in childhood biliary atresia. Pediatrics. https:\/\/doi.org\/10.1542\/peds.2015-4453","journal-title":"Pediatrics"},{"issue":"7","key":"691_CR70","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1507\/endocrj.EJ16-0587","volume":"64","author":"J Feng","year":"2017","unstructured":"Feng J et al (2017) The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J 64(7):675\u2013683","journal-title":"Endocr J"},{"key":"691_CR71","first-page":"1539","volume-title":"Tumor-induced osteomalacia","author":"MT Collins","year":"2020","unstructured":"Collins MT et al (2020) Chapter 64. Tumor-induced osteomalacia. Academic, New York, pp 1539\u20131552"},{"issue":"3","key":"691_CR72","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1530\/ERC-11-0006","volume":"18","author":"WH Chong","year":"2011","unstructured":"Chong WH et al (2011) Tumor-induced osteomalacia. Endocr Relat Cancer 18(3):R53\u2013R77","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"691_CR73","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.anl.2017.05.006","volume":"45","author":"SV Kane","year":"2018","unstructured":"Kane SV et al (2018) Phosphaturic mesenchymal tumor of the nasal cavity and paranasal sinuses: a clinical curiosity presenting a diagnostic challenge. Auris Nasus Larynx 45(2):377\u2013383","journal-title":"Auris Nasus Larynx"},{"issue":"10","key":"691_CR74","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jama.294.10.1260","volume":"294","author":"SM Jan de Beur","year":"2005","unstructured":"Jan de Beur SM (2005) Tumor-induced osteomalacia. JAMA 294(10):1260\u20131267","journal-title":"JAMA"},{"key":"691_CR75","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000381000","volume":"28","author":"J Allgrove","year":"2015","unstructured":"Allgrove J, Shaw NJ (2015) A practical approach to vitamin D deficiency and rickets. Endocr Dev 28:119\u2013133","journal-title":"Endocr Dev"},{"issue":"6","key":"691_CR76","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.bone.2008.02.014","volume":"42","author":"I Endo","year":"2008","unstructured":"Endo I et al (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 42(6):1235\u20131239","journal-title":"Bone"},{"issue":"2","key":"691_CR77","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","author":"F Francis","year":"1995","unstructured":"Francis F et al (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11(2):130\u2013136","journal-title":"Nat Genet"},{"issue":"11","key":"691_CR78","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ng1905","volume":"38","author":"JQ Feng","year":"2006","unstructured":"Feng JQ et al (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38(11):1310\u20131315","journal-title":"Nat Genet"},{"issue":"2","key":"691_CR79","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ajhg.2010.01.010","volume":"86","author":"V Levy-Litan","year":"2010","unstructured":"Levy-Litan V et al (2010) Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86(2):273\u2013278","journal-title":"Am J Hum Genet"},{"issue":"7","key":"691_CR80","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D et al (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15(7):435\u2013455","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"691_CR81","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/hmg\/ddt429","volume":"23","author":"YH Lim","year":"2014","unstructured":"Lim YH et al (2014) Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet 23(2):397\u2013407","journal-title":"Hum Mol Genet"},{"issue":"5","key":"691_CR82","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/00000441-199105000-00006","volume":"301","author":"K Konishi","year":"1991","unstructured":"Konishi K et al (1991) Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis. Am J Med Sci 301(5):322\u2013328","journal-title":"Am J Med Sci"},{"issue":"4925","key":"691_CR83","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/bmj.1.4925.1311","volume":"1","author":"PD Saville","year":"1955","unstructured":"Saville PD et al (1955) Osteomalacia in Von Recklinghausen\u2019s neurofibromatosis; metabolic study of a case. Br Med J 1(4925):1311\u20131313","journal-title":"Br Med J"},{"issue":"2","key":"691_CR84","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1086\/427956","volume":"76","author":"KE White","year":"2005","unstructured":"White KE et al (2005) Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76(2):361\u2013367","journal-title":"Am J Hum Genet"},{"issue":"9","key":"691_CR85","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1073\/pnas.0712361105","volume":"105","author":"CA Brownstein","year":"2008","unstructured":"Brownstein CA et al (2008) A translocation causing increased \u03b1-Klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 105(9):3455\u20133460","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"691_CR86","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1067\/j.cpradiol.2018.06.005","volume":"48","author":"M Yang","year":"2019","unstructured":"Yang M et al (2019) Molecular imaging in diagnosis of tumor-induced osteomalacia. Curr Probl Diagn Radiol 48(4):379\u2013386","journal-title":"Curr Probl Diagn Radiol"},{"issue":"26","key":"691_CR87","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa010839","volume":"345","author":"J Seufert","year":"2001","unstructured":"Seufert J et al (2001) Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 345(26):1883\u20131888","journal-title":"N Engl J Med"},{"key":"691_CR88","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2014.04.016","volume":"64","author":"S Breer","year":"2014","unstructured":"Breer S et al (2014) 68Ga DOTA-TATE PET\/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT\/CT. Bone 64:222\u2013227","journal-title":"Bone"},{"issue":"10","key":"691_CR89","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1210\/jc.2016-2052","volume":"101","author":"D El-Maouche","year":"2016","unstructured":"El-Maouche D et al (2016) Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab 101(10):3575\u20133581","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"691_CR90","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1210\/jc.2004-0406","volume":"89","author":"Y Takeuchi","year":"2004","unstructured":"Takeuchi Y et al (2004) Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 89(8):3979\u20133982","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"691_CR91","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/jbmr.316","volume":"26","author":"P Andreopoulou","year":"2011","unstructured":"Andreopoulou P et al (2011) Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res 26(6):1295\u20131302","journal-title":"J Bone Miner Res"},{"issue":"1","key":"691_CR92","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12957-015-0763-7","volume":"14","author":"J Dadoniene","year":"2016","unstructured":"Dadoniene J et al (2016) Tumour-induced osteomalacia: a literature review and a case report. World J Surg Oncol 14(1):4","journal-title":"World J Surg Oncol"},{"issue":"1","key":"691_CR93","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1530\/EJE-13-0581","volume":"170","author":"S Piemonte","year":"2014","unstructured":"Piemonte S et al (2014) Six-year follow-up of a characteristic osteolytic lesion in a patient with tumor-induced osteomalacia. Eur J Endocrinol 170(1):K1\u2013K4","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"691_CR94","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00223-018-0429-x","volume":"103","author":"L Colangelo","year":"2018","unstructured":"Colangelo L et al (2018) A challenging case of tumor-induced osteomalacia: pathophysiological and clinical implications. Calcif Tissue Int 103(4):465\u2013468","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"691_CR95","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1093\/rheumatology\/39.12.1415","volume":"39","author":"GP Clunie","year":"2000","unstructured":"Clunie GP, Fox PE, Stamp TC (2000) Four cases of acquired hypophosphataemic (\u2018oncogenic\u2019) osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatology (Oxf) 39(12):1415\u20131421","journal-title":"Rheumatology (Oxf)"},{"key":"691_CR96","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12891-015-0496-3","volume":"16","author":"ZJ Sun","year":"2015","unstructured":"Sun ZJ et al (2015) Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors. BMC Musculoskelet Disord 16:43","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"691_CR97","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s11926-015-0512-5","volume":"17","author":"AH Hautmann","year":"2015","unstructured":"Hautmann AH et al (2015) Tumor-induced osteomalacia: an up-to-date review. Curr Rheumatol Rep 17(6):512","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"691_CR98","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1210\/jc.2013-2528","volume":"98","author":"VD Tarasova","year":"2013","unstructured":"Tarasova VD et al (2013) Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy. J Clin Endocrinol Metab 98(11):4267\u20134272","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"691_CR99","doi-asserted-by":"publisher","first-page":"e10178","DOI":"10.1002\/jbm4.10178","volume":"3","author":"SK Mishra","year":"2019","unstructured":"Mishra SK et al (2019) Successful management of tumor-induced osteomalacia with radiofrequency ablation: a case series. JBMR Plus 3(7):e10178","journal-title":"JBMR Plus"},{"issue":"4","key":"691_CR100","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF03343720","volume":"23","author":"QL Huang","year":"2000","unstructured":"Huang QL, Feig DS, Blackstein ME (2000) Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia. J Endocrinol Investig 23(4):263\u2013267","journal-title":"J Endocrinol Investig"},{"issue":"9","key":"691_CR101","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1210\/jc.2004-0724","volume":"89","author":"A Gupta","year":"2004","unstructured":"Gupta A et al (2004) FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 89(9):4489\u20134492","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"691_CR102","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1359\/jbmr.070304","volume":"22","author":"JL Geller","year":"2007","unstructured":"Geller JL et al (2007) Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 22(6):931\u2013937","journal-title":"J Bone Miner Res"},{"issue":"8","key":"691_CR103","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/jbmr.3162","volume":"32","author":"D Ovejero","year":"2017","unstructured":"Ovejero D et al (2017) Octreotide is ineffective in treating tumor-induced osteomalacia: results of a short-term therapy. J Bone Miner Res 32(8):1667\u20131671","journal-title":"J Bone Miner Res"},{"key":"691_CR104","doi-asserted-by":"crossref","unstructured":"Paglia F, Dionisi S, Minisola S (2002) Octreotide for tumor-induced osteomalacia. N Engl J Med 346(22):1748\u20131749; author reply 1748\u20131749","DOI":"10.1056\/NEJM200205303462215"},{"key":"691_CR105","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-OR13-1","author":"S Jan De Beur","year":"2019","unstructured":"Jan De Beur S et al (2019) OR13-1 burosumab improves the biochemical, skeletal, and clinical symptoms of tumor-induced osteomalacia syndrome. J Endocr Soc. https:\/\/doi.org\/10.1210\/js.2019-OR13-1","journal-title":"J Endocr Soc"},{"issue":"10","key":"691_CR106","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/jbmr.478","volume":"26","author":"S Wohrle","year":"2011","unstructured":"Wohrle S et al (2011) FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res 26(10):2486\u20132497","journal-title":"J Bone Miner Res"},{"issue":"4","key":"691_CR107","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/jbmr.1810","volume":"28","author":"S Wohrle","year":"2013","unstructured":"Wohrle S et al (2013) Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res 28(4):899\u2013911","journal-title":"J Bone Miner Res"},{"key":"691_CR108","unstructured":"Collins MT et al (2015) Striking response of tumor-induced osteomalacia to the FGFR inhibitor NVP-BGJ398. In: American Society of Bone and Mineral Research annual meeting 2015, Seattle, WA"},{"key":"691_CR109","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fonc.2019.00179","volume":"9","author":"C Fumarola","year":"2019","unstructured":"Fumarola C et al (2019) Expanding the arsenal of FGFR inhibitors: a novel chloroacetamide derivative as a new irreversible agent with anti-proliferative activity against FGFR1-amplified lung cancer cell lines. Front Oncol 9:179","journal-title":"Front Oncol"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-020-00691-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-020-00691-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-020-00691-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T19:16:41Z","timestamp":1622834201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-020-00691-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["691"],"URL":"https:\/\/doi.org\/10.1007\/s00223-020-00691-6","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"14 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The NIDCR receives financial support from QED Pharma to study BGJ398 in tumor-induced osteomalacia. The Pontificia Universidad Cat\u00f3lica de Chile (PF, MJ) receives research support from Ultragenyx Pharmaceutical, Inc. for research related to hypophosphatemic rickets. Work in the Laboratories of IH, KR, RG, MC is supported by the Intramural Research Program of the NIH, NIDCR.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}